Evaluación del efecto citotóxico de péptidos derivados de la secuencia LfcinB (21-25)Pal: RWOWRWQWR frente a líneas celulares humanas derivadas de cáncer de mama
| dc.contributor.advisor | García Castañeda, Javier Eduardo | spa |
| dc.contributor.author | Barragán Cárdenas, Andrea Carolina | spa |
| dc.contributor.researchgroup | Síntesis y aplicación de moléculas peptídicas | spa |
| dc.date.accessioned | 2020-03-03T20:01:37Z | spa |
| dc.date.available | 2020-03-03T20:01:37Z | spa |
| dc.date.issued | 2019 | spa |
| dc.description.abstract | El cáncer de mama actualmente presenta la mayor incidencia y mortalidad en mujeres a nivel mundial, los diferentes tratamientos para esta enfermedad son altamente invasivos afectando tanto la calidad de vida como la autoestima de los pacientes. Es por esto, que se requieren nuevos abordajes terapéuticos con mayor selectividad que no induzcan resistencia ni generen efectos adversos. Dentro de este contexto surgen los péptidos antimicrobianos (AMPs) los cuales han presentado efecto citotóxico contra células cancerosas; el péptido palindrómico derivado de lactoferricina bovina LfcinB (21-25hat: 1 RWQWRWQWR9 ha presentado actividad anticancerígena contra líneas celulares humanas derivadas de cáncer oral y de mama. En este trabajo se evaluó el efecto citotóxico de péptidos análogos de la secuencia palindrómica (sean de Alaninas) frente a líneas derivadas de cáncer de mama MDA-MB-468, MDA-MB-231, MCF- 7 y cultivo primario de fibroblastos, determinando que el efecto citotóxico se ve disminuido por la modificación de cualquiera de los residuos de la secuencia. El péptido palindrómico generó efecto citotóxico selectivo sobre las líneas celulares evaluadas con cambios morfológicos característicos de apoptosis. Además, se evaluó de manera preliminar el tipo de muerte celular generada por este péptido contra la línea celular MCF-7 mediante citometría de flujo y cambio en la expresión génica relativa , permitiéndonos determinar que su efecto está mediado mayoritariamente por procesos apoptóticos. Este trabajo permitió identificar un péptido citotóxico y selectivo contra líneas celulares derivadas de cáncer de mamá, cuya secuencia puede ser considerada promisoria para el desarrollo de agentes terapéuticos. | spa |
| dc.description.abstract | Breast cancer currently has the highest incidence and mortality in women worldwide, the different treatments for this disease are highly invasive affecting both the quality of life and the self-esteem of patients. That is why new therapeutic approaches with greater selectivity which do not induce resistance or generate adverse effects are required. Within this context, antimicrobial peptides (AMPs) arise which have had a cytotoxic effect against cancer cells; palindromic peptide derived from bovine lactoferricin LfcinB (21-25hat: 1RWQWRWQWR9 has presented anticancer activity against human celllines derived from oral and breast cancer. In this work, the cytotoxic effect of peptide analogs of the palindromic sequence (Alanine sean) was evaluated against lines derived from breast cancer MDA-MB-468, MDA-MB-231, MCF-7 and primary fibroblast culture, determining that the cytotoxic effect is diminished by the modification of any of the sequence residues. The palindromic peptide generated a selective cytotoxic effect on celllines evaluated with morphological changes characteristic of apoptosis. In addition, the mechanism of action of this peptide against the MCF-7 cellline was evaluated preliminary by flow cytometry and change in relative gene expression, supporting us to determine that its effect is mediated by apoptotic processes. This work allowed to identify a cytotoxic and selective peptide against celllines derived from breast cancer, whose sequence can be considered promising for the development of therapeutic agents. | spa |
| dc.description.additional | Magíster en Ciencias - Bioquímica. | spa |
| dc.description.degreelevel | Maestría | spa |
| dc.format.extent | 110 | spa |
| dc.format.mimetype | application/pdf | spa |
| dc.identifier.uri | https://repositorio.unal.edu.co/handle/unal/75809 | |
| dc.language.iso | spa | spa |
| dc.publisher.branch | Universidad Nacional de Colombia - Sede Bogotá | spa |
| dc.publisher.department | Departamento de Química | spa |
| dc.relation.references | [1] J. Gifford, H. Hunter y H. Vogel, «Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties,» Cellular and Molecular Life Sciences, vol. 62, pp. 2588–2598,, 2005. [2] I. Zubairu, K. Babagana, D. Danlami, L. Abdullahi y A. Khan, «Molecular Therapeutic Cancer Peptides: A Closer Look at Bovine Lactoferricine,» Asian Journal of Biochemistry, Genetics and Molecular Biology, pp. 1-9, 2018. [3] N. D. J. Huertas Méndez, Y. Vargas Casanova, A. K. Gómez Chimbi, E. Hernández, A. L. Leal Castro, J. M. Melo Diaz, Z. J. Rivera Monroy y J. E. García Castañeda, «Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Antimicrobial Activity against E. coli ATCC 11775, S. maltophilia ATCC 13636 and S. enteritidis ATCC 13076,» Molecules, vol. 22, pp. 1-10, 2017. [4] NIH, «Instituto Nacional del Cáncer,» 2018. [En línea]. Available: https://www.cancer.gov/espanol/publicaciones/diccionario/buscar?contains=false&q=cancer. [5] D. Hanahan y R. A. Weinberg, «Hallmarks of Cancer: The Next Generation,» Cell, vol. 144, nº 5, pp. 646-674, 2011. [6] World Health Organization, «World Health Organization,» 2019. [En línea]. Available: https://www.who.int/health-topics/cancer#tab=tab_1. [7] World Cancer Research Fund, «Worldwide cancer data,» 2018. [En línea]. Available: https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data. [8] G. W. Prager, S. Baraga, B. Bystricky, C. Qvortrup, C. Criscitiello, E. Esin, G. S. Sonke, G. Argilés-Martínez, J.-S. Frenel, M. Karamouzis, M. Strijbos, O. Yazici, P. Bossi, S. Banerjee, T. Troiani, A. Eniu, F. Ciardiello, J. Tabernero, C. Zielinski, P. Casali, F. Cardoso, . J.-Y. Douillard, S. Jezdic, K. McGregor, G. Bricalli, M. Vyas y . A. Ilbawi, «Global cancer control: responding to the growing burden, rising costs and inequalities in access,» ESMO Caner Horizons, 2018. [9] IARC, «Latest global cancer data:Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018,» WHO, Lyon , 2019. [10] C. Pardo y R. Cendales, «Estimaciones de incidencia y mortalidad para los principales cinco tipos de cáncer en Colombia, 2007-2011,» Colombia Médica, vol. 49, nº 1, 2018. [11] C. Pardo y E. de Vries, «Breast and cervical cancer survival at Instituto Nacional de Cancerología, Colombia,» Colombia Médica, vol. 49, nº 1, pp. 102-108, 2018. [12] E. Vergara-Dagobeth, A. Suárez-Causado y R. D. Gómez-Arias, «Plan Control del cáncer en Colombia 2012-2021. Un análisis formal,» Rev Gerenc Polít Salud., pp. 6-18, 2017. [13] B. H. L. Howes, D. I. Watson, C. Xu, B. Fosh, M. Canepa y N. R. Dean, «Quality of Life Following Total Mastectomy with and without Reconstruction versus Breast-Conserving Surgery for Breast Cancer: A Case-Controlled Cohort Study,» J. Plast. Reconstr. Aesthetic Surg., vol. 69, nº 9, p. 1184–1191, 2016. [14] Breast Cancer Now, «Side effects,» 5 2019. [En línea]. Available: https://breastcancernow.org/information-support/facing-breast-cancer/going-through-breast-cancer-treatment/side-effects/side-effects-radiotherapy. [15] J. Fernebro, «Fighting bacterial infections-future treatment options.,» Drug Resist Updat, vol. 14, nº 2, pp. 125-139, 2011. [16] J. Castañeda, J. Ortega, A. Vanegas, A. Aquino, J. Serafin, S. Estrada y I. Estrada, «Péptidos antimicrobianos: péptidos con múltiples funciones,» Alergia, asma e inmunología pediatricas, vol. 18, nº 1, pp. 16-29, 2009. [17] K. Kurrikoff, D. Aphkhazava y U. ̈. Lange, «The future of peptides in cancer treatment,» Current opinion in pharmacology, vol. 47, p. 27–32, 2019. [18] The Global Cancer Observatory, «Breast cancer statistics worldwide,» World Health Organization, 2019. [19] A. Di Sibio, G. Abriata, D. Forman y M. Sierra, «Female breast cancer in Central and South America,» Female breast cancer in Central and South America, pp. 110-120, 09 2016. [20] J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. Maxwell, D. Forman y F. Bray, «Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012,» International Journal of Cancer, pp. 359-386, 13 09 2014. [21] Ministerio de Salud y Protección Social; Instituto de Evaluación Tecnológica en Salud; Instituto Nacional de Cancerología, «Guía de Práctica Clínica para la detección temprana, trtamiento integral, seguimiento y rehanilitación del cáncer de mama,» 2017. [En línea]. Available: http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Conv_500/GPC_cancer_mama/gpc_cancer_mama_completa.aspx. [22] L. Acuña, A. Sanchéz, L. Soler, F. Valderrama, M. Daza, L. Moreno, P. Ramírez, A. Niño y A. Rodríguez, «Lucha contra el cáncer de mama,» Boletín de información Técnica Especializada de la Cuenta de Alto Costo., vol. 3, nº 18, pp. 1-5, 19 10 2017. [23] G. Sharma, R. Dave, J. Sanadya, P. Sharma y K. Sharma, «Various types and management of breast cancer: an overview.,» Journal of Advanced Pharmaceutical Technology and Research, vol. 2, nº 1, pp. 109-126, 2010. [24] M. Roland-Mieszkowsk, «Cancer - A Biophysicist's Point of View,» Digital Recordings, Halifax, 2004. [25] A. Santaballa, «Cáncer de mama,» Sociedad Española de Oncología Médica, Madrid, 2017. [26] M. A. Kosir, «Breast Cancer,» Merck & Co., Inc., Kenilworth, 2018. [27] F. Imigo, E. Mansilla, I. Delama, M. T. Poblete y C. Fonfach, «Clasificación molecular del cáncer de mama,» Cuadernos de cirugía , vol. 25, pp. 67-74, 2011. [28] M. Arrechea-Irigoyen, F. Vicente-García, A. Córdoba-Iturriagagoitia, B. Ibáñez-Beroiz, M. Santamaría-Martínez y F. Guillén-Grima, «Subtipos moleculares del cáncer de mama: implicaciones pronósticas y características clínicas e inmunohistoquímicas,» Anales del Sistema Sanitario de Navarra, vol. 34, nº 2, pp. 219-233, 2011. [29] S. K. Al-Ghazal, L. Fallowfield y R. W. Blamey, «Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction.,» European Journal of Cancer, vol. 36, nº 15, pp. 1938-1943, 2000. [30] Asociación Española Contra el Cáncer, «Cáncer de mama,» AECC, Madrid, 2014. [31] M. Clarke, R. Collins, S. Darby, C. Davies, P. Elphinstone, V. Evans, J. Godwin, R. Gray, C. Hicks, S. James, E. MacKinnon, P. McGale, T. McHugh, R. Peto, C. Taylor y Y. Wang, «Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.,» The Lancet, vol. 366, nº 9503, pp. 2087-2106, 2005. [32] J. Tao, K. Visvanathan y A. Wolf, «Long term side effects of adjuvant chemotherapy in patients with early breast cancer.,» Breast, vol. 24, nº 2, pp. 149-153, 2015. [33] American Cancer Society, Inc, «Treating Breast Cancer,» 26 9 2017. [En línea]. Available: https://www.cancer.org/cancer/breast-cancer/treatment/hormone-therapy-for-breast-cancer.htmL. [34] National Institutes of Health, «Hormone Therapy for Breast Cancer,» 14 2 2017. [En línea]. Available: https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet. [35] K. Holland y M. Bien, «Breast Cancer Hormone Therapy: How It Works, Side Effects, and More,» 8 9 2016. [En línea]. Available: https://www.healthline.com/health/breast-cancer-hormone-therapy-how-it-works-side-effects-more. [36] K. V. Reddy, R. Yedery y C. Aranha, «Antimicrobial peptides: premises and promises.,» International Journal of Antimicrobial Agents, vol. 24, nº 6, pp. 536-547, 2004. [37] M. Mahlapuu, J. Håkansson, L. Ringstad y C. Björn, «Antimicrobial Peptides: An Emerging Category of Therapeutic Agents,» Frontiers in cellular and infection microbiology, vol. 6, pp. 1-12, 2016. [38] D. Hoskin y A. Ramamoorthy, «Studies on anticancer activities of antimicrobial peptides,» Biochimica et Biophysica Acta 1778, pp. 357-375, 2008. [39] G. Wang, B. Mishra, K. Lau, T. Lushnikova, R. Golla y X. Wang, «Antimicrobial Peptides in 2014,» Pharmaceuticals, nº 8, pp. 123-150, 2015. [40] T. Iwasaki, J. Ishibashi, H. Tanaka, M. Sato, A. Asaoka, D. Taylor y M. Yamakawa, «Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface,» Peptides, pp. 660-668, 2009. [41] B. Deslouches y Y. P. Di, «Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications,» Oncotarget, vol. 28, nº 8, p. 46635–46651, 2017. [42] W. Shoombuatong, N. Schaduangrat y C. Nantasenamat, « Unraveling the bioactivity of anticancer peptides as deduced from machine learning.,» Journal of experimental and clinical sciences, vol. 17, p. 734–752, 2018. [43] Y. Yoo, S. R. Watanabe, K. Watanabe, K. Hata, K. Shimazaki y I. Azuma, «Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice,» Japanese Journal of Cancer, vol. 88, pp. 184-190, 1997. [44] M. Kentaro, S. Yasushi, H. Yoshihiko, N. Yuko y M. Yasuki, «Protein-surfactant interactions between bovine lactoferrin and sophorolipids under neutral and acidic conditions,» Biochemistry and Cell Biology, vol. 95, nº 1, pp. 126-132, 2017. [45] L. Barreto, «Efecto de la lactoferrina bovina en la invasión de Salmonella typhimurium cepa SL 1344 a células HEp-2,,» Universidad Nacional Mayor de San Marcos, Lima, 2017. [46] M. Drago, «Lactoferrina: producción industrial y aplicaciones,» Revista Mexicana de Ciencias Farmacéuticas, vol. 38, nº 3, pp. 30-38, 2007. [47] R. Jiang y B. Lönnerdal, «Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells (HT-29) by activating various signaling pathways,» Biochemistry & Cell Biology, vol. 95, p. 99–109, 2017. [48] A. Richardson, R. de Antueno, R. Duncan y D. W. Hoskin, «Intracellular delivery of bovine lactoferricin’s antimicrobial core (RRWQWR) kills T-leukemia cells,» Biochemical and Biophysical Research Communications, vol. 388, nº 4, pp. 736-741, 2009. [49] V. Solarte, «Péptidos derivados de la lactoferricina bovina como agentes anticancerígenos contra el carcinoma de células escamosas de la cavidad oral,» Universidad Nacional de Colombia, Bogotá, 2016. [50] J. S. Mader, J. Salsman, D. M. Conrad y D. W. Hoskin, «Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines,» Molecular Cancer Therapeutics, vol. 4, nº 4, pp. 612-624, 2005. [51] A. Solarte, P. Conget, J. Vernott, J. Rosas, J. García, Z. Rivera y M. Arango, «A tetrameric peptide derived from bovine lactoferricin as a potential therapeutic tool for oral squamous cell carcinoma: A preclinical model,» PLOS ONE, pp. 1-17, 2017. [52] V. A. Solarte, J. E. Rosas, Z. J. Rivera, M. L. Arango-Rodríguez, J. E. García y J.-P. Vernot, «A Tetrameric Peptide Derived from Bovine Lactoferricin Exhibits Specific Cytotoxic Effects against Oral Squamous-Cell Carcinoma Cell Lines,» BioMed Research Internationa, pp. 1-13, 2015. [53] Y. Vargas, J. Rodríguez, Y. Umañana, A. Leal, G. Almanzar, J. Garcia y Z. Rivera, «Antibacterial Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Cytotoxic Effect against MDA-MB-468 and MDA-MB-231 Breast Cancer Cell Lines,» Molecules, pp. 1-11, 2017. [54] J. Rodríguez Guerra, A. Barragán Cárdenas, A. Ochoa-Zarzosa, J. López Meza, A. Umaña Pérez, R. Fierro-Medina, Z. J. Rivera Monroy y J. E. García Castañeda, «The tetrameric peptide LfcinB (20–25)4 derived from bovine lactoferricin induces apoptosis in the MCF-7 breast cancer cell line,» RSC Advances, vol. 9, p. 20497–20504, 2019. [55] R. Fine, P. Brandt-Rouf y Y. Mao..Estados Unidos Patente 7,772,367, 2005. [56] L. Migliolo, M. R. Felício, M. H. Cardoso, O. N. Silva, M.-A. E. Xavier, D. O. Nolasco, A. S. de Oliveira, I. Roca-Subira, J. V. Estape, L. D. Teixeira, S. M. Freitas, A. J. Otero-Gonzalez, S. Gonçalves , N. C. Santos y O. L. Franco, «Structural and functional evaluation of the palindromic alanine-rich antimicrobial peptide Pa-MAP2,» Biochimica et Biophysica Acta journal, vol. 1858, nº 7, p. 1488–1498, 2016. [57] C. Sun, Y. Li, S. Cao, H. Wang y C. Jiang, «Antibacterial Activity and Mechanism of Action of Bovine Lactoferricin Derivatives with Symmetrical Amino Acid Sequences,» Internationa Journal of Molecular Sciences, vol. 19, pp. 1-20, 2018. [58] M. B. Strøm, B. E. Haug, M. L. Skar, W. Stensen, T. Stiberg y J. Svendsen, «The Pharmacophore of Short Cationic Antibacterial Peptides,» Journal of medicinal chemistry, pp. 1567-1570, 2003. [59] K. Burns, T. McCleery y D. Thévenin, «pH-Selective Cytotoxicity of pHLIP-Antimicrobial Peptide Conjugates,» Scientific Reports, pp. 1-10, 2016. [60] J. Rodriguez, «Evaluación De La Actividad Anticancerígena In Vitro De Péptidos Sintéticos Derivados De Lactoferricina Bovina En Líneas Celulares De Cáncer De Mama,» Universidad Nacional de Colombia, Bogotá, 2019. [61] J. Oh, S. Y. Hong y K. H. Lee, «Structure-activity relationship study : short an timicrobial peptides,» The Journal of Peptide Research, vol. 53, nº 1, pp. 41-46, 1999. [62] B. Pignataro, New Strategies in Chemical Synthesis and Catalysis,, John Wiley & Sons, Incorporated, 2012. [63] A. Guarna y A. Trabocchi, Peptidomimetics in Organic and Medicinal Chemistry, John Wiley & Sons, Incorporated, 2014. [64] A. Beck-sickiniger, H. Weiland, H. Wittneben, K. Willim y K. J. G. Rudolf, «Complete L-alanine scan of neurpeptide y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations,» European Journal of Biochemistry, pp. 947-958, 1994. [65] American Type Culture Collection, «MDA-MB-468 (ATCC® HTB-132™,» 2016. [En línea]. Available: https://www.atcc.org/Products/All/HTB-132.aspx#culturemethod.. [66] X. Dai, H. Cheng, Z. Bai y J. Li, «Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping,» Journal of Cancer, vol. 16, nº 8, pp. 3131-3141, 2017. [67] American Type Culture Collection, «MDA-MB-231 (ATCC® HTB-26™),» 2018. [En línea]. Available: https://www.atcc.org/Products/All/HTB-26.aspx#documentation. [68] American Type Culture Collection, «MCF7 (ATCC® HTB-22™,» 2016. [En línea]. Available: https://www.atcc.org/Products/All/HTB-22.aspx#documentation. [69] M. Lacroix y G. Leclercq, «Relevance of breast cancer cell lines as modelsfor breast tumours: an update,» Breast Cancer Research and Treatment, vol. 83, p. 249–289, 2004. [70] D. Wu, Y. Gao, Y. Qi, L. Chen, Y. Ma y Y. Li, «Peptide-based cancer therapy: Opportunity and challenge,» Cancer Letters, pp. 13-22, 2014. [71] X. Ke y L. Shen, «Molecular targeted therapy of cancer: The progress and future prospect,» Frontiers in Laboratory Medicine, pp. 69-75, 2017. [72] J. van Meerloo, G. Kaspers y J. Cloos, «Cell Sensitivity Assays: The MTT Assay,» de Cree, I, Springer Science+Business Media, 2011, pp. 237-245. [73] BioLegend, «FITC Annexin V Apoptosis Detection Kit with 7-AAD,» 30 11 2012. [En línea]. Available: https://www.biolegend.com/en-gb/global-elements/pdf-popup/fitc-annexin-v-apoptosis-detection-kit-with-7-aad-8264?filename=FITC Annexin V Apoptosis Detection Kit with 7-AAD.pdf&pdfgen=true. [74] Invitrogen, «TRIzol reagent,» Thermo Fisher Scientific, Carlsbad, 2016. [75] P. Chomczynski y N. Sacchi, «Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction,» Analytical Biochemistry, pp. 156-159, 1987. [76] N. d. J. Huertas, Z. J. Rivera Monroy, R. Fierro Medina y J. E. García Casañeda, «Antimicrobial Activity of Truncated and Polyvalent Peptides Derived from the FKCRRQWQWRMKKGLA Sequence against Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923,» Molecules, vol. 22, nº 6, 2017. [77] S. Reißer, E. Strandberg, T. Steinbrecher y A. Ulrich, «3D Hydrophobic Moment Vectors as a Tool to Characterize the Surface Polarity of Amphiphilic Peptides,» Biophysical Journal, vol. 106, pp. 2385-2394, 2016. [78] M. Jaimes Melo, «PREDICCIÓN IN-SILICO DE LA ESTRUCTURA Y FUNCIÓN DE LA PROTEÍNA HIPOTÉTICA p284 DE Trypanosoma cruzi,» PONTIFICIA UNIVERSIDAD JAVERIANA, Bogotá, 2012. [79] N. Yang, M. B. Strøm, S. M. Mekonnen, J. S. Svendsenc y ø. Rekdal, «The Effects of Shortening Lactoferrin Derived Peptides against Tumour Cells, Bacteria and Normal Human Cells,» Journal of Peptide Science, vol. 10, p. 37–46, 2004. [80] J. H. Kang, M. K. Lee, K. L. Kim y K. S. Hahm, «Structure-biological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin,» International Journal of Peptide and Protein Research, vol. 4, nº 357-363, p. 48, 1996. [81] S. Farnaud y R. Evans, «Lactoferrin - a multifunctional protein with antimicrobial properties,» Molecular Immunology, vol. 40, nº 7, pp. 395-405, 2003. [82] L. T. Eliassen, G. Berge, A. Leknessund, M. Wikman, I. Lindin, C. Løkke, F. Ponthan, J. I. Johnsen, B. Sveinbjørnsson, P. Kogner, T. Flægstad y Ø. Rekdal, «The antimicrobial peptide, Lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and exhibits xenographt growth in vivo,» International Journal of Cancer, vol. 119, p. 493–500, 2006. [83] Molecular Probes, «MitoProbe™ JC-1 Assay Kit for Flow Cytometry (M34152),» ThermoFisher Sientific, Eugene, 2011. [84] A. Roseto y C. Brenner, «Apoptosis o la muerte celular programada,» Archivos Argentinos de Pediatria, pp. 253-275, 1999. [85] J. A. Gibbon, J. R. Kanwar y R. K. Kanwar, «Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer,» BMC Cancer., vol. 15, 2015. [86] M. Á. Ramírez-García, H. Márquez-González, G. Barranco-Lampón y J. E. López-Aguila, «Bcl-2: su papel en el ciclo celular, apoptosis y cáncer,» El Residente, vol. 9, nº 3, pp. 84-94, 2014. [87] L. K. Leung y T. T. Wang, «Bcl-2 Is Not Reduced in the Death of MCF-7 Cells at Low Genistein Concentration,» The Journal of Nutrition, vol. 130, nº 12, p. 2922–2926, 2000. [88] N. Pilco-Ferreto y G. M. Calaf, «Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines,» INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 49, pp. 753-762, 2016. | spa |
| dc.rights | Derechos reservados - Universidad Nacional de Colombia | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.license | Atribución-NoComercial-SinDerivadas 4.0 Internacional | spa |
| dc.rights.spa | Acceso abierto | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | spa |
| dc.subject.proposal | Lactoferricina bovina | spa |
| dc.subject.proposal | Bovine lactoferricin | eng |
| dc.subject.proposal | Palindromic peptide | eng |
| dc.subject.proposal | Péptido palindrómico | spa |
| dc.subject.proposal | Cáncer de mama | spa |
| dc.subject.proposal | Breast cancer | eng |
| dc.subject.proposal | Selectividad | spa |
| dc.subject.proposal | Selectivity | eng |
| dc.subject.proposal | Citotoxicidad | spa |
| dc.subject.proposal | Cytotoxicity | eng |
| dc.title | Evaluación del efecto citotóxico de péptidos derivados de la secuencia LfcinB (21-25)Pal: RWOWRWQWR frente a líneas celulares humanas derivadas de cáncer de mama | spa |
| dc.type | Trabajo de grado - Maestría | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_bdcc | spa |
| dc.type.coarversion | http://purl.org/coar/version/c_ab4af688f83e57aa | spa |
| dc.type.content | Text | spa |
| dc.type.driver | info:eu-repo/semantics/masterThesis | spa |
| dc.type.version | info:eu-repo/semantics/acceptedVersion | spa |
| oaire.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |